PL1 peptide

PL1 is a tumor-homing peptide with the amino acid sequence PPRRARVT, designed to specifically target the extracellular matrix (ECM) of solid tumors. It binds with high affinity to Tenascin-C (TNC) and Fibronectin (specifically the extra domain B, FN-EDB, and extra domain A, FN-EDA), which are glycoproteins overexpressed in the remodeling stroma of various cancers but largely absent in normal adult tissues. Developed by researchers at the University of Tartu, PL1 is utilized as a targeting moiety to deliver therapeutic payloads, such as nanoparticles, small molecules, or cytokines, directly into the tumor microenvironment. In the context of sarcoma, PL1 has been shown to localize to TNC-rich immunosuppressive niches that typically exclude T-cells, suggesting its potential to improve the delivery and efficacy of immunotherapies and cell-based treatments like TCR-T by overcoming stromal barriers.

Other names

PL1 homing peptidePL-1 homing peptidePL 1 homing peptidePPRRARVT